Function said the capital will allow the company to bring its platform to millions more people faster.
“Our mission is simple: enable you to live one hundred healthy years,” said Jonathan Swerdlin, co-founder and CEO of Function. “Everyone deserves to feel their best and avoid suffering. Every dollar invested in Function is a vote for one hundred healthy years for eight billion people. This growth financing allows us to pull the inevitable and optimistic future of health into the present.”
Function wants consumers to live one hundred healthy years by enabling access to gold standard lab testing, MRI and CT as part of annual health checks. Function’s Medical Intelligence Lab works to develop a continuous learning system that predicts the future of one’s health and next steps. The screenings, which start at $365 a year, give access to over 160 lab tests and covers heart, hormones, thyroid, liver, kidneys, heavy metal exposures, nutrient levels, inflammation, potential cancer signals, among other tests.
“[General Catalyst’s] financing reflects our belief that Function is one of the defining companies of our generation,” said Pranav Singhvi, partner and co-head of CVF, General Catalyst. “Function has created an entirely new approach to health that we have never had before. We believe Function is uniquely positioned to reach millions more people, and we’re proud to support the next phase of its growth.”
In November, Function announced it had raised $298 million in Series B funding, backed by both venture capital and celebrity investors like Matt Damon and Zac Efron.
Back-to-back acquisitions
Launched in 2023, Function has already expanded with the acquisition of Getlabs’ nationwide at-home or office blood draw network.
Function said the deal, announced in April, removed barriers to healthcare access, including challenges connected to travel, scheduling and mobility. By bringing licensed specialists directly to a member’s location, Function said it supports greater access for the individual to health data.
In June, Function announced its acquisition of supplement intelligence platform SuppCo to advance biomarker testing, imaging, clinician guidance and supplement recommendations.
“SuppCo’s independent supplement evaluation and TrustScore verify what’s worth taking,” Swerdlin said at the time. “The result is a system that recommends based on your biology, verifies what you’re putting in your body and measures whether it’s working.”
Function said it wants to make that “system” more intelligent through AI to help identify patterns earlier and deliver more contextual recommendations to create clearer connections between daily behaviors and measurable outcomes.
